Who Can Get Ozempic for Weight Loss?

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has transformed weight management for millions, with clinical trials showing average weight loss of 15% over 68 weeks at therapeutic doses. However, access to this medication depends on specific health criteria, BMI thresholds, and medical history. PlexusDx simplifies eligibility by offering compounded semaglutide through licensed 503A pharmacies nationwide, making personalized GLP-1 therapy more accessible than traditional Ozempic prescriptions.

Medical Eligibility Requirements for Semaglutide

Semaglutide candidacy begins with a BMI assessment and metabolic health evaluation. Adults with a BMI of 30 or higher, or those with a BMI of 27 or higher plus weight-related health conditions like type 2 diabetes or hypertension, generally qualify for treatment. PlexusDx providers review individual medical histories to confirm suitability before initiating therapy.

Beyond BMI metrics, patients must have no contraindications to GLP-1 medications, including personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2). A baseline health assessment screens for kidney function, liver status, and gastrointestinal conditions that may influence treatment safety. This personalized evaluation ensures semaglutide aligns with your unique metabolic profile.

Age matters too—semaglutide injections are approved for adults 18 and older, though clinical data on long-term outcomes is strongest in adults over 45. Pregnant individuals or those planning pregnancy should avoid semaglutide, as it may affect fetal development. PlexusDx providers discuss timing and family planning goals during the initial consultation.

How PlexusDx Expands Access Beyond Traditional Prescribing

Traditional Ozempic prescriptions often require insurance approval, lengthy prior-authorization delays, or cash prices exceeding $900 per month. PlexusDx partners with licensed 503A compounding pharmacies to deliver pharmaceutical-grade semaglutide at a flat rate at $189/mo month-to-month, or from $149/mo on the 6-month plan—no flat per-compound pricing fluctuations and no membership fees. This model serves all 50 states without insurance gatekeeping.

Compounded semaglutide from 503A facilities meets pharmaceutical standards for purity, potency, and sterility, though it differs from FDA-approved Ozempic in manufacturing location and regulatory pathway. PlexusDx patients enjoy HSA/FSA eligibility, transparent pricing, and rapid prescription fulfillment. Your dose may need to go up during your treatment journey. Your price won't.

The elimination of insurance requirements removes barriers for uninsured, underinsured, or self-employed individuals seeking semaglutide therapy. PlexusDx also offers oral semaglutide as an alternative for patients uncomfortable with injections, at $289/mo month-to-month, or from $249/mo on the 6-month plan.

Genetic Factors That Influence Semaglutide Response

Not every patient responds identically to semaglutide, and genetic variation plays a measurable role in treatment outcomes. The GLP1R rs6923761 variant affects GLP-1 receptor sensitivity, while GIPR rs1800437 influences appetite-signaling pathways. Individuals carrying specific alleles may experience faster or slower weight loss trajectories and varying side-effect profiles.

PlexusDx offers the Precision Peptide Genetic Test—a peptide-pathway genetic assessment that maps 14 metabolic pathways and 49 peptide markers across 150+ genetic insights. This test identifies your inherited predispositions to appetite regulation, satiety signals, and metabolic efficiency, informing personalized semaglutide dosing strategies. At $298, this test removes guesswork from GLP-1 selection.

Genetic testing also informs whether tirzepatide (which targets both GLP-1 and GIP receptors) might outperform semaglutide for your biology. PlexusDx integrates genetic data into treatment planning, helping patients achieve optimal outcomes faster than trial-and-error approaches.

Pre-Treatment Assessment and Getting Started

PlexusDx initiates treatment with a comprehensive intake questionnaire covering medical history, current medications, previous weight-loss attempts, and lifestyle factors. A licensed provider reviews your profile, discusses realistic outcomes, and clarifies expectations—average first-month weight loss typically ranges from 3–8 pounds as your body adjusts to appetite-suppression signaling. This assessment determines your starting dose and whether semaglutide injection, oral semaglutide, or a combination therapy best suits your needs.

Once approved, PlexusDx ships medication directly to your home with clear injection instructions, storage guidelines, and 24/7 support access. Follow-up appointments at weeks 2 and 4 track tolerance, side effects, and weight response. Many patients gradually increase doses over 4–12 weeks until reaching their therapeutic target, while maintaining the same monthly subscription rate.

Patients with underlying conditions—diabetes, cardiovascular disease, or prior GI surgery—receive additional monitoring protocols. PlexusDx coordinates with your primary care physician if desired, ensuring semaglutide integrates seamlessly with your broader health plan. HSA and FSA accounts cover all medication costs, maximizing tax-advantaged savings.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Do I need insurance to qualify for PlexusDx semaglutide?

No. PlexusDx serves patients with or without insurance across all 50 states. Compounded semaglutide is $189/mo month-to-month, or from $149/mo on the 6-month plan with no membership fees, and HSA/FSA accounts are eligible for payment. Insurance is never required.

What if I have type 2 diabetes—does that change my semaglutide eligibility?

Type 2 diabetes actually strengthens your candidacy for semaglutide, as the medication improves blood glucose control while driving weight loss. PlexusDx providers assess your current diabetes management and coordinate dosing to avoid hypoglycemia if you're taking other diabetes medications. Discuss your insulin or sulfonylurea use during your initial consultation.

How quickly will I see weight loss results on semaglutide?

Most PlexusDx patients notice appetite suppression within 3–5 days and measurable weight loss within 2–4 weeks. Clinical trials show average first-month losses of 3–8 pounds, accelerating as your dose increases toward therapeutic levels. Individual results vary based on diet, exercise, and genetic factors.

What are the most common side effects, and who should avoid semaglutide?

Mild nausea, constipation, and reduced appetite are common early side effects that typically fade within 1–2 weeks. Serious contraindications include personal/family history of medullary thyroid cancer, MEN 2 syndrome, or severe kidney disease. Pregnancy, breastfeeding, and recent GI surgery also warrant avoidance. PlexusDx providers screen for all contraindications during intake.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. PlexusDx's Precision Peptide Genetic Test identifies variants in GIPR and FTO, and MC4R genes that influence semaglutide response and satiety signaling. At $298, this test reveals whether semaglutide or tirzepatide aligns better with your peptide pathways, accelerating your path to optimal dosing.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.